Stock Track | Twist Bioscience Plummets 5.97% Intraday After Reporting Wider-Than-Expected Quarterly Loss

Stock Track
05/04

Twist Bioscience Corporation's stock plummeted 5.97% during intraday trading on Monday, following the release of its fiscal second-quarter 2026 financial results.

The significant drop came despite the company reporting quarterly sales of $110.7 million, which exceeded analyst estimates. Investors focused on the wider-than-anticipated net loss, which expanded to $44 million, or $0.71 per diluted share. This result missed the FactSet consensus estimate of a $0.50 loss per share. On an adjusted basis, the loss of $0.59 per share also fell short of the $(0.48) estimate.

While Twist Bioscience raised its full-year revenue outlook to a range of $442 million to $447 million, the substantial earnings miss appears to have driven negative sentiment, overshadowing the positive revenue guidance update.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10